MARCH 26TH 2019; IMPACT BREAKFAST:
Program:
08:00-08:30 : Registration and breakfast
08:30-08:35: Opening by Karl-Christian Agerup, Oslotech/Forskningsparken
08:35-08:50: Jan Magnus Aronsen UiO and Jonas Skogestad OUS:
PDE2 inhibition: A novel and specific treatment for ventricular arrhythmias
08:50-09:05: Ana Lobato Pascual OUS:
OptimOva™, personalised in vitro fertilisation treatment
09:05-09:20: Ole Marius Hoel Rindal, UiO:
Efficiently massaging medical ultrasound data
09:20-09:35: Joachim Paasche, SINTEF:
Roboglass - Vision-based intelligence applied to industrial robots
09:35-09:40: Brief sum up
Refill your coffee, networking.
10:00: Finish
More about the speakers and their presentations:
Jan Magnus Aronsen, associate professor UiO/Bjørknes College, MD PhD-student and Jonas Skogestad, medical doctor and PhD at dep. of experimental science, Oslo University Hospital
PDE2 inhibition: A novel and specific treatment for ventricular arrhythmias
Ventricular arrhythmias are a major cause of morbidity and mortality in patients with cardiac disease, with millions of patients worldwide dying every year. Current treatments for ventricular arrhythmias are often ineffective and have potentially serious side effects, and there is an unmet need for more efficacious and safer therapies. Our invention is to reposition existing inhibitors of phosphodiesterase 2 (PDE2), earlier developed for various diseases in the central nervous system, to prevent ventricular arrhythmias. Our experimental results show that PDE2 inhibitors directly target the underlying disease mechanism with high specificity and potency, and with a molecular mechanism that is expected to minimize side effects compared to present treatment options. The goal of this project is to clinically test PDE2-inhibitors as a novel and first-in-class therapy for prevention of ventricular arrhythmias.
Ana Lobato Pascual, Research Coordinator and PhD at the Reproductive Medicine group, Oslo University Hospital
OptimOva™, personalised in vitro fertilisation treatment
Ninety-one percent of women who undergo IVF receive stimulating hormones to achieve a pregnancy. IVF treatment success is based on the production of multiple egg cells through a daily injection of stimulating hormones. Estimation of hormone dosage is a key challenge since the dose needs to be finely adjusted to avoid too low or high hormone responses. Currently, routine dosing procedures lead to 23 % treatment cancellation. In Europe, this means around 200,000 treatments per year are cancelled annually.
Currently, no method for personalised hormone dosage exists, and indirect methods together with doctor’s clinical experience are commonly employed. We have patented and clinically validated a blood test that utilises a cell biomarker value, unique for each patient, thus making VF treatment more precise and optimised for the patient needs. OptimOva™ is an in vitro diagnostics medical device kit which fine-tunes the doctor’s hormone dose estimation.
Ole Marius Hoel Rindal, Doctoral Research Fellow - Research Group for Digital Signal Processing and Image Analysis, Institutt for Informatikk, UiO
Efficiently massaging medical ultrasound data
The democratization of medical ultrasound imaging brings clinically valid imaging to your smartphone. This revolution is driven by software beamforming, exploiting the increasing computer power available in modern devices. The flexibility in software beamforming allows smarter ways of exploiting the information available in the ultrasound data. One way of efficiently massaging the right information out of the data will be presented.
Joachim Paasche, Kjeller Innovasjon og SINTEF
Roboglass: Vision-based intelligence applied to industrial robots
Global sales of industrial robots increased by 31% from 2016 to 2017. Still, a lot of industries are relying on manual human labor since robots today have no intelligence which limits their use to simple and repetitive tasks.
Roboglass combines 3D sensor data with a unique path planning algorithm to give vision and intelligence to robots. This enables easier programming of the robot, the ability to do more complex tasks and collaboration between human and robots. Dialog with the industry shows that vision based robot applications are an important part of their future strategy. We are currently in process of exploring our options and finding the best strategic position for our technology.